Jie Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jie Wang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Fanchen Meng
Department of Thoracic Surgery, Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research , Nanjing
42 shared publications - Hua Bao
Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, PR China
42 shared publications - Jing You
Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P.R. China
42 shared publications - Jingyuan Zhang
Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, P.R. China
42 shared publications - Lin Xu
Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Department of Thoracic Surgery, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China
42 shared publications - Peng Chen
Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P.R. China
42 shared publications
Latest Publications
- 20 September 2023
- Published by American Physical Society (APS) in Physical Review B
- Vol. 108 (11) , 115141
Thermopower of the dice lattice
The Dice lattice structure is similar to the graphene honeycomb lattice, but with an imbalance atom in each hexagon center giving rise to a dispersionless flat band, which intersects the pseudopsin Dirac bands through the Dirac point. In this work, we report a theoretical study on the thermopower of the Dice lattice by focusing on the role of the flat band and comparison with the graphene case. Based on the Chebyshev polynomials Green's function method, we show that an extra pair of thermopower peaks near the band center appear in the Dice lattice compared to the graphene counterpart due to the presence of the flat band. In the relatively high temperature regime, the emergent thermopower peaks exhibit an unconventional dependence on temperature and disorder contrary to the Mott's relation, and the origin is ascribed to the extreme narrow bandwidth of the broadened flat band. We also discuss the enhancement of the thermopower by introducing an energy gap in the Dice lattice.- 20 September 2023
- Published by American Physical Society (APS) in Physical Review B
- Vol. 108 (11) , 115141
Thermopower of the dice lattice
The Dice lattice structure is similar to the graphene honeycomb lattice, but with an imbalance atom in each hexagon center giving rise to a dispersionless flat band, which intersects the pseudopsin Dirac bands through the Dirac point. In this work, we report a theoretical study on the thermopower of the Dice lattice by focusing on the role of the flat band and comparison with the graphene case. Based on the Chebyshev polynomials Green's function method, we show that an extra pair of thermopower peaks near the band center appear in the Dice lattice compared to the graphene counterpart due to the presence of the flat band. In the relatively high temperature regime, the emergent thermopower peaks exhibit an unconventional dependence on temperature and disorder contrary to the Mott's relation, and the origin is ascribed to the extreme narrow bandwidth of the broadened flat band. We also discuss the enhancement of the thermopower by introducing an energy gap in the Dice lattice.- Open Access
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Study design and flow chart of methodology. A, Cohort and study design. B, Fragmentomics feature extraction and modeling details.
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Study design and flow chart of methodology. A, Cohort and study design. B, Fragmentomics feature extraction and modeling details.
- Open Access
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Additional methods for Coxnet models
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Additional methods for Coxnet models
- Open Access
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Evaluating longitudinal fragmentomics model prediction and ctDNA status
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Evaluating longitudinal fragmentomics model prediction and ctDNA status
- Open Access
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Recursive feature elimination with cross-validation of Coxnet model using fragmentomics profiles
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Recursive feature elimination with cross-validation of Coxnet model using fragmentomics profiles
- Open Access
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Additional methods for Coxnet models
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Additional methods for Coxnet models
- Open Access
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Univariate and multivariate Cox analysis of risk factors
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Univariate and multivariate Cox analysis of risk factors
- Open Access
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Study design and flow chart of methodology. A, Cohort and study design. B, Fragmentomics feature extraction and modeling details.
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Study design and flow chart of methodology. A, Cohort and study design. B, Fragmentomics feature extraction and modeling details.
- Open Access
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Progression-free survival analysis using fragmentomics model–predicted risk status and ctDNA mutation profile. A and B, 7 days and 6 months postsurgical prognosis based on fragmentomics model–predicted risk status. C and D, 7 days and 6 months postsurgical prognosis based on ctDNA mutation profile–predicted risk status. E and F, 7 days and 6 months postsurgical prognosis based on combination of fragmentomics model and ctDNA mutation profile–predicted risk status. A combined high-risk patient was defined as being model-predicted high risk or ctDNA positive.
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Progression-free survival analysis using fragmentomics model–predicted risk status and ctDNA mutation profile. A and B, 7 days and 6 months postsurgical prognosis based on fragmentomics model–predicted risk status. C and D, 7 days and 6 months postsurgical prognosis based on ctDNA mutation profile–predicted risk status. E and F, 7 days and 6 months postsurgical prognosis based on combination of fragmentomics model and ctDNA mutation profile–predicted risk status. A combined high-risk patient was defined as being model-predicted high risk or ctDNA positive.
- Open Access
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Leave-one-out cross-validation (LOOCV) results of Coxnet model using fragmentomics profiles. A, ROC curves for both 7 days and 6 months postsurgical models. B and C, Barplots for model-predicted risk scores for 7 days and 6 months postsurgical models.
- 30 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Leave-one-out cross-validation (LOOCV) results of Coxnet model using fragmentomics profiles. A, ROC curves for both 7 days and 6 months postsurgical models. B and C, Barplots for model-predicted risk scores for 7 days and 6 months postsurgical models.